Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Northrup leaves Enzi: With Democrats poised to take the lead of the Senate Health, Education, Labor & Pensions (HELP) Committee, outgoing Chairman Michael Enzi's (R-Wyo.) health policy director Stephen Northrup, former executive director of the Medical Device Manufacturers Association, moves to the law firm Arent Fox Dec. 13 as senior government relations director. David Bowen, health policy director to Sen. Edward Kennedy (D-Mass.), likely will take over as majority director of health policy for the HELP committee in January, when Kennedy is expected to become chairman. The HELP committee has primary jurisdiction in the Senate over FDA activities...

You may also be interested in...



Baxter Sheds Poorly Performing Blood Products Line For $540 Mil.

Baxter will sell its blood collection and processing business to a pair of investment firms for $540 mil., it announced Oct. 3

Chembio Clears Path For HIV Tests With Patent, Marketing Agreement

Chembio settled its legal disputes and found a marketing partner for its recently approved rapid HIV tests in a three-party agreement announced Oct. 5

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel